The company is not selling any of its common stock pursuant to this prospectus, and will not receive any proceeds from the sale of its common stock offered by this prospectus by the selling stockholders.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRZN:
- Surrozen’s Strategic Shift to Ophthalmology and Wnt Pathway Innovations Justify Buy Rating
- Surrozen Focuses on Ophthalmology Amid Financial Challenges
- Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year
- Surrozen Secures $76.4M in Private Placement Deal
- Surrozen to focus Wnt expertise, technologies on ophthalmology programs